O-007Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (20th June 2018) - Rossini, D; Cremolini, C; Conca, E; Del Re, M; Busico, A; Pietrantonio, F; Bergamo, F; Danesi, R; Cardellino, G; Tamburini, E; Dell'Aquila, E; Strippoli, A; et al.